This has been another bad week for the Palo Alto-based consumer blood testing company, Theranos. Since last year, the start-up has been dogged by regulatory troubles.
A newly released federal inspection report, by the Centers for Medicare and Medicaid Services (CMS), has found that the company's testing devices often fail the firm’s own accuracy requirements.
The 121 page redacted report about Theranos’s Newark laboratory, revealed that the company’s much touted finger-prick blood tests failed quality control checks nearly 30 percent of the time.
John Carreyrou is an investigative reporter for The Wall Street Journal who has been covering Theranos and first reported the story today. He told KQED’s Danielle Venton that the company's pattern has been to criticize any information made public by others.
“This data is important because it comes directly from the company. The company can't say, 'well this person or that person has an agenda and they are out to get us'. This is their own data," says Carreyrou.